Cardiotoxicity is a known risk of anthracycline treatment. However, the relative contribution of anthracyclines to the development of congestive heart failure (CHF), when included in a poly-chemotherapy regimen, is unclear. We examined cardiotoxicity in adult patients with diffuse large B-cell lymphoma and follicular lymphoma undergoing first-line immunochemotherapy from 2000-2012. In total, 2440 patients without previous heart disease were identified from the Danish Lymphoma Registry, of which 1994 (81Á7%) were treated with anthracycline-containing chemotherapy [R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R-CHOEP (R-CHOP + etoposide)] and 446 (18Á3%) were treated without anthracyclines (reference group). Compared to the reference group, the adjusted hazard ratio of CHF after 3-5 cycles of R-CHOP/ CHOEP was 5Á0 [95% confidence interval (CI) 1Á4; 18Á5], 6 cycles 6Á8 (95% CI 2Á0; 23Á3) and >6 cycles 13Á4 (95% CI 4Á0; 45Á0). The cumulative 5-year risk of CHF with all-cause mortality as competing risk was 4Á6% after 3-5 cycles of R-CHOP/CHOEP, 4Á5% after 6 and 7Á9% after more than 6 cycles. Cumulative 5-year risk for patients treated without anthracyclines was 0Á8%. Using anthracyclines in first-line lymphoma treatment increases risk of CHF in patients without previous history of heart disease. In particular, treatment with >6 cycles of R-CHOP/CHOEP is associated with a significant increase in CHF rate.
Anthracycline-induced CHF exhibits a dose-response relationship; cumulative doses of doxorubicin >550 mg/m 2 were associated with 30% risk of CHF whereas cumulative doses ≤550 mg/m 2 conferred a 0Á3% risk (Lefrak et al, 1973) . However, recommended contemporary first-line lymphoma treatment does not exceed 8 cycles of R-CHOP, corresponding to 400 mg/m 2 (50 mg/m 2 doxorubicin per cycle) (Zelenetz et al, 2014; Tilly et al, 2015) . Even so, the well-established risk of cardiotoxicity has spurred a general precaution against the use of anthracyclines in the elderly patient population, particularly those with a previous history of cardiovascular disease (CVD) (Hershman et al, 2008) . Mitigating the risk of cardiotoxicity in elderly patients by using treatment alternatives without anthracyclines could be at the expense of poorer disease control and worse survival (Grann et al, 2006) . Recent data from a US study based on the "Surveillance, Epidemiology, and End Results" and "Medicare" (SEER-Medicare) database showed only slightly increased risk of CHF among elderly DLBCL patients treated with anthracyclines as compared to those treated without chemotherapy, but treatment without chemotherapy is unusual in DLBCL and suggests a potential selection bias in the reference population (Hershman et al, 2008) . Furthermore, the actual reduction in risk of cardiac disease obtainable from using non-anthracycline-based treatments in patients considered at high risk of cardiotoxicity is not well studied. Series that compare incidental cardiac disease in lymphoma patients treated with anthracyclines to the similar risk in a matched background population could potentially overestimate the cardiotoxic effects of anthracyclines because lymphoma in general, as well as surveillance bias arising from being frequently consulted by physicians, may be associated with cardiotoxicity and increased likelihood of being diagnosed with CVD. Of note, other drugs included in the R-CHOP regimen such as rituximab, cyclophosphamide and vincristine, have been causally linked to cardiotoxicity (Mandel et al, 1975; Mills & Roberts, 1979; Gottdiener et al, 1981; Goldberg et al, 1986; Foran et al, 2000; Renard et al, 2013) . In this Danish nationwide study, we examined the risk of cardiac disease (CHF and CVD) in a cohort of patients with DLBCL or follicular lymphoma (FL) treated with immunochemotherapy with or without anthracyclines in first-line.
Methods

Patient inclusion
This is a retrospective cohort study based on the Danish National Lymphoma Registry (LYFO), which is a Danish registry for quality control of lymphoma treatment. It has been nationwide since year 2000 and contains detailed information on adult patients treated for lymphoma in Denmark (Arboe et al, 2016) . As a rule, data in LYFO is prospectively entered and includes a large variety of baseline clinicopathological features, treatment details and date of relapse/death. The coverage and quality of LYFO were validated in a recent study that compared LYFO data to information from the Danish Cancer Registry and local medical files. Nationwide data completeness was very high (94Á4-100%) and data accuracy ranged between 93Á4-100% with the exception of the albumin variable, which was 87Á1% (Arboe et al, 2016) . In the present study, patients were included in the anthracycline-treated cohort if following criteria were met: (i) newly diagnosed DLBCL or FL between 2000-2012, (ii) ≥16 years of age at diagnosis and (iii) ≥3 cycles of R-CHOP or R-CHOEP (R-CHOP + etoposide) upfront. Patients treated with less than 3 cycles of R-CHOP/CHOEP were not included, as this is not consistent with routine practice and we suspect early cessation of chemotherapy to be at least partially explained by occurrence of severe adverse events. Patients treated with regimens more intensive than R-CHOP/ CHOEP and up-front high-dose therapy with autologous stem cell transplantation were excluded. The group of patients treated without anthracyclines consisted of FL and DLBCL patients treated with regimens such as CVP (cyclophosphamide, vincristine and prednisolone), chlorambucil or CEOP (cyclophosphamide, etoposide, vincristine and prednisolone) in combination with rituximab.
Patients with CVD before first pathological diagnosis of lymphoma were excluded because the purpose of the study was to analyse incidental cases of CHF and CVD, but also to avoid confounding by indication as selection of treatment without anthracyclines could have been motivated by preexisting heart disease (Appendix S1).
Events
The Danish National Patient Register is governed by the Danish Health Authority and contains data on all hospital admissions since 1977 and all outpatient activities since 1995 (Lynge et al, 2011) . By using the unique civil registration numbers assigned to all Danish citizens (CPR number), events were retrieved from the registry using the International Classification of Diseases 10th revision (ICD-10) code "Congestive Heart Failure" (ICD-10: I50) to identify CHF and the following ICD-10 codes for CVD: "Ischaemic Heart Disease" (ICD-10: I20-I25), "Atrial fibrillation and flutter" (ICD-10: I48), "Ventricular fibrillation and flutter" (ICD-10: I490) and "Congestive Heart Failure" (ICD-10: I50). Thus, CHF was analysed as a single entity but was also included in the broader CVD term.
Comorbidities were identified from the Danish National Patient Registry based on registered disease diagnoses within 5 years prior to the inclusion date of each patient (Appendix S2).
Statistical analysis
Continuous variables are presented as medians with 1st and 3rd quartile cut-off values (Q1-Q3) and compared using the Kruskal-Wallis test, whereas categorical variables were compared using the chi-squared test. Patient follow-up started from 30 days after completion of chemotherapy to minimize confounding by early cardiotoxicity on the number of R-CHOP treatments received. To test that results were robust regardless of start of follow-up, a sensitivity analysis, with follow-up beginning 90 days after completion of chemotherapy, was conducted. Follow-up ended when an event (CHF or CVD) occurred, on the day of emigration from Denmark, death, relapse or the end of the study (31 December 2014), whichever came first. Patients with relapse were censored as we explicitly intended to explore the contribution of anthracyclines to cardiotoxicity and not intensive salvage therapies. Patients exposed to anthracyclines were grouped according to the number of R-CHOP/CHOEP treatments (3-5, 6 and >6 cycles). Univariate and multivariable Cox regression analyses were performed to examine the association between anthracycline treatments and cardiotoxicity. Covariates in the Cox analyses included sex, age, radiotherapy, World Health Organization performance status, number of R-CHOP/ CHOEP treatments, comorbidities and histology (FL or DLBCL) . Cycle length (14 vs. 21 days) was only included in the univariate analysis. Cumulative incidence curves were computed to illustrate risk of CHF and CVD by number of R-CHOP/CHOEP cycles with all-cause mortality as competing risk. Overall survival analyses estimates were calculated with entry being 30 days after end of treatment and until death or censoring at the end of study or the date of emigration. The study population was defined using SAS Software 9.4 (SAS Institute, Cary, NC, USA) and all statistical analyses were made using R version 3.4.1 (R Core Team, 2013) . The study was approved by the Danish Data Protection Agency (2008-58-0028) .
Results
Patients
A total of 2440 patients met the inclusion criteria; 1994 patients were treated with anthracycline-containing chemotherapy (R-CHOP or R-CHOEP) and 446 patients were treated without anthracyclines (mostly CVP, chlorambucil and CEOP, all in combination with rituximab). Patients treated with anthracyclines were predominantly diagnosed with DLBCL (88Á0%), whereas patients treated without anthracyclines were more frequently diagnosed with FL (78Á3%). Among patients treated with anthracyclines, 371 (18Á6%) were treated with 3-5 cycles of R-CHOP/CHOEP, 1032 patients (51Á8%) 6 cycles and 591 (29Á6%) received >6 cycles. Patients treated with reduced cycles of anthracyclines (3-5) were older (median age 67 years, 40Á2% over 70 years), more likely to have Ann Arbor stage 1 lymphoma (62Á6%), and more received a combined modality treatment with radiotherapy (49Á1%). In comparison, patients treated with more than 6 cycles were youngest (median age 62, 21Á8% over 70 years), least likely to have Ann Arbor stage 1 lymphoma (7Á4%), and 11Á7% received a combined modality treatment with radiotherapy. Patients treated with reduced cycles (3-5) were most likely to receive R-CHOP/CHOEP at 21 days intervals (72Á6% vs. 36Á1% for patients receiving >6 cycles). Patients treated without anthracyclines rarely received radiotherapy consolidation (4Á0%) ( Table I) .
Median follow-up was 3Á8 years for patients treated with anthracyclines and 3Á9 years for patients treated without anthracyclines. During this time, 659 deaths occurred [539 (27Á0%) and 120 (26Á9%) in patients treated with or without anthracyclines, respectively] resulting in 5-year overall survival estimates of 85% [95% confidence interval (CI) 83; 87] for the whole cohort, 86% (95% CI 84; 88) for anthracycline-treated patients, and 81% (95% CI 77; 86) for patients treated without anthracyclines (Fig 1) .
Congestive heart failure (CHF)
A total of 108 (5Á4%) patients treated with anthracyclines developed CHF as compared to 3 (0Á7%) patients treated without anthracyclines. Cumulative CHF incidences with allcause mortality as competing risk were evaluated according to the number of R-CHOP/CHOEP treatments; patients treated with 3-5 cycles of R-CHOP/CHOEP had 1-, 5-and 8-year risks of 0Á6%, 4Á6% and 5Á2%, patients treated with 6 cycles had risks of 1Á0%, 4Á5% and 8Á1% and patients treated with >6 cycles had risks of 4Á0%, 7Á9% and 9Á4%. The corresponding risk estimates for patients treated without anthracyclines were 0%, 0Á8%, and 1Á6% (Fig 2) . Cumulative incidences of all-cause mortality without CVD according to treatment group is shown in Figure S1 . In a sensitivity analysis with follow-up starting 90 days after completion of chemotherapy, no major changes in the cumulative risk of CHF were noted ( Figure S2 ).
The unadjusted hazard ratio (HR) for CHF for patients treated with 3-5 cycles was 5Á7 (95% CI 1Á7; 19Á8), patients treated with 6 cycles had a HR of 6Á3 (95% CI 2Á0; 20Á4) and patients treated with >6 cycles had a HR of 10Á9 (95% CI 3Á4; 34Á9). Cycle length for R-CHOP/CHOEP (14 days vs. 21 days), radiotherapy or sex were not associated with an increased risk of CHF. When adjusting for sex, age, radiotherapy, comorbidities and histology (FL or DLBCL) in the multivariable Cox regression, HR for CHF in patients treated with 3-5 cycles of R-CHOP/CHOEP was 5Á0 (95% CI 1Á4; 18Á5), 6Á8 (95% CI 2Á0; 23Á3) for those treated with 6 cycles and 13Á4 (95% CI 4Á0; 45Á0) for those who received >6 cycles. Age was a risk factor for CHF in both the adjusted and unadjusted analysis (Table II) . In a sub-analysis of 3 vs. 6 cycles of R-CHOP/CHOEP, the unadjusted HR for CHF for patients treated with 6 cycles compared to 3 was 1Á0 (95% CI 0Á5; 1Á8) and the adjusted HR was 1Á1 (95% CI 0Á5; 2Á2).
Three-year overall survival estimates following CHF were 76% (95% CI 68; 85) for all patients (Fig 3) . 
Cardiovascular disease (CVD)
In total, 243 (12Á2%) of the patients treated with anthracyclines developed CVD compared to 23 (5Á2%) patients treated without anthracyclines. Cumulative incidences of CVD with all-cause mortality as competing risk were evaluated according to the number of R-CHOP/CHOEP treatments: Patients treated with 3-5 cycles of R-CHOP/CHOEP had 1-, 5-, and 8-year risks of 2Á5%, 10Á5% and 17Á2%, respectively, the corresponding risks for patients treated with 6 cycles were 2Á1%, 9Á3% and 21Á2% and, for patients treated with >6 cycles, they were 5Á9%, 15Á5% and 21Á7%. The risk estimates for patients treated without anthracyclines were 1Á7%, 6Á3% and 7Á8% (Fig 4) . Cumulative incidences of allcause mortality without CVD according to treatment group is shown in Figure S1 . In a sensitivity analysis with follow- up starting 90 days after completion of chemotherapy, no major changes in the cumulative risk of CVD were noted ( Figure S3 ).
Compared to patients treated without anthracyclines, the unadjusted HR for CVD for patients treated with 3-5 cycles was 2Á1 (95% CI 1Á3; 3Á5), patients treated with 6 cycles had a HR of 2Á0 (95% CI 1Á3; 3Á1) and patients treated with >6 cycles had a HR of 2Á9 (95% CI 1Á8; 4Á5). Cycle length for R-CHOP/CHOEP (14 days vs. 21 days), radiotherapy and sex did not have an impact on the risk of developing CVD. When adjusting for sex, age, radiotherapy, comorbidities and histology (FL or DLBCL) in the multivariable Cox regression, HR for patients treated with 3-5 cycles was 2Á0 (95% CI 1Á1; 3Á6), 2Á1 (95% CI 1Á2; 3Á5) for those who received 6 cycles and 3Á2 (95% CI 1Á9; 5Á3) for patients treated with >6 cycles. Age was a risk factor for CVD in both the adjusted and unadjusted analysis (Table III) .
Discussion
This cohort study compared the risk of CHF and CVD in the treatment of lymphoma with anthracycline-containing regimens versus treatment without anthracyclines. Patients receiving anthracyclines clearly had higher risks of CHF and CVD when compared to patients treated without anthracyclines, for whom the overall risk was negligible. In particular, high risk of CHF was observed for patients treated with more than 6 cycles of R-CHOP/CHOEP with a cumulative incidence of 9Á4% after 8 years. Overall, this study confirms that the inclusion of anthracyclines in a multi-agent immunochemotherapy regimen and not immunochemotherapy in general is responsible for cardiotoxicity following lymphoma treatment.
Cardiotoxicity related to anthracyclines has been classified as a type 1 toxicity (irreversible injury to the heart) (Volkova & Russell, 2011) . Formation of free radicals in the metabolism of doxorubicin is speculated to be the main driver of the toxic effects to the heart (Davies & Doroshow, 1986) . The free radical activates apoptotic pathways in the cells, probably leading to injury of the cardiac mitochondria cells and cardiomyocytes (Volkova & Russell, 2011) . Three types of anthracycline-induced cardiotoxicity have been defined according to time of onset; (i) "Acute" cardiotoxicity with clinical manifestations developing in the weeks after the first dose of anthracycline, (ii) "Early onset chronic" seen in the first year after receiving anthracyclines, and (iii) "late onset chronic" cardiotoxicity, which can manifest after several years or even decades of receiving anthracyclines (Cardinale et al, 2015) . Our aim was to look at the "early onset chronic" and "late onset chronic" cardiotoxicities. True "acute" cases of cardiotoxicity were probably excluded from our analysis as follow-up began 30 days after end of chemotherapy. This delay was intentionally selected to avoid confounding by early cardiotoxicity in relation to type of chemotherapy and number of treatment cycles. In a sensitivity analysis with follow-up starting 90 days after completion of chemotherapy, the results were generally comparable with no major changes in CHF and CVD incidence. Earlier studies report inconsistent results regarding the cumulative anthracycline dose needed to cause cardiotoxicity in a substantial fraction of patients. Lefrak et al (1973) reported a 30% risk of CHF after cumulative doses above 550 mg/m 2 of doxorubicin, whereas Limat et al (2003) found increased risk at lower cumulative doses, i.e., more than 200 mg/m 2 . LYFO includes information on the number of treatment cycles given, but not dosing information. Therefore, we used number of treatment cycles as a surrogate estimate for dose, assuming that each cycle contained 50 mg/m 2 doxorubicin. However, data from a recent Danish study including review of >1000 medical charts from elderly DLBCL patients have shown that dose reductions are common for elderly patients, with only 59% of 75-to 79-year-old patients scheduled for full dosing complete therapy without dose reductions and even fewer for those older than 79 years (Juul et al, 2018) . Therefore, our study may underestimate the true dose-response relationship between anthracyclines and cardiotoxicity. The true magnitude of cardiotoxicity may also be underestimated by the fact that 18Á6% of R-CHOP/CHOEP treated patients in the present study received less than 6 cycles of R-CHOP/CHOEP. These patients were older (median age 66Á5 vs. 61Á6 years for >6 cycles, P < 0Á01) and more patients belonged to the +70 years group (40Á2% vs. 21Á8% for >6 cycles, P < 0Á01).
The competing risk for all-cause mortality without CVD ( Figure S1 ) shows that patients treated with less than 6 cycles of R-CHOP/CHOEP had the highest all-cause mortality, suggesting that this group is frailer than those receiving 6 cycles or more. Whether higher cumulative anthracycline dose in those patients would have increased risk of cardiotoxicity is unknown. Our database also lacks information on radiotherapy site, which has been associated with CHF in Hodgkin lymphoma survivors if radiation doses to the myocardium exceeded 20 Gy (van Nimwegen et al, 2017). We did not see any association between radiotherapy and cardiotoxicity in our study, potentially reflecting the fact that mediastinal irradiation is uncommon in DLBCL. Another important aspect is that historical data on the relationship between radiotherapy and cardiotoxicity does not necessarily reflect risks with modern radiotherapy. A simulation study has shown significantly lower radiation to the cardiac area when modern radiotherapy techniques are implemented (Maraldo et al, 2013) , which is also confirmed in a Swedish populationbased study estimating lower future risk of excess cardiovascular deaths in patients treated in the era of modern radiotherapy (Eloranta et al, 2013) .
Other investigators examined CVD in childhood cancer survivors according to whether they had been exposed to cardiotoxic therapy (anthracycline, radiation to the heart, plant alkaloids, alkylating agents, etc.) or not and compared incidence of CVD to sibling controls (Lipshultz et al, 2012) . Results showed that childhood cancer survivors, even those not exposed to anthracyclines or cardiac irradiation, had higher incidence of cardiovascular abnormalities, more systemic inflammation (higher levels of CRP), higher levels of NT-proBNP, and an increased risk of atherosclerotic disease. Subsequently, childhood cancer survivors not exposed to anthracyclines were found to be at a higher risk of cardiovascular diseases compared to cancer-free sibling controls (Lipshultz et al, 2012) . Thus, comparison of CVD incidence in lymphoma patients to a background population may overestimate the perceived cardiotoxic effects of anthracyclines. For this reason, we chose to compare anthracycline-treated patients to patients treated with immunochemotherapy not including anthracyclines.
In a study by Cardinale et al (2015) , where CHF was defined as a reduction in left ventricular ejection fraction (LVEF) >10% units from baseline or a LVEF below 50%, showed that almost all cases of CHF following anthracycline treatment were detected within the first year of follow-up with a median time of 3Á5 months following last dose of anthracyclines. The median time to CHF following treatment in our study was 4 years and 6 months and only 34 (30Á6%) developed CHF within the first year of follow-up. This reflects the fact that we only captured symptomatic CHF leading to hospital contact and suggest that our study underestimates the true rate of cardiotoxicity by not capturing discrete CHF cases.
As anticipated, pre-existing cardiovascular risk factors, such as hypertension, dyslipidaemia and diabetes, are associated with increased risk of CHF following anthracycline treatment (Salz et al, 2017) . The study by Salz et al (2017) was also based on the Danish lymphoma registry, but exclusively investigated CHF and not CVD in general and with a broader definition of CHF by inclusion of several more ICD-10 codes compared to our study (I11Á0, I13Á0, I13Á2, I50, I50Á0, I50Á1, and I50Á9 vs. I150 in the present study). Overall, 92% of the patients in this study received anthracyclines and patients with a previous history of cardiac disease were, unlike in the present study, included in the study reported by Salz et al (2017) . Anthracycline-induced cardiotoxicity has been considered irreversible by some investigators (Volkova & Russell, 2011) .
However, Cardinale et al (2015) found that early detection and CHF treatment allowed for partial (LVEF increase >5% absolute points and >50%, with the absence of CHF symptoms) and, in some cases, full recovery (LVEF increase to the baseline value). For patients with anthracycline-induced cardiotoxicity enrolled before 1999, enalapril was promptly initiated and from 1999 beta-blockers were added to this treatment (Cardinale et al, 2015) . Although not tested in a randomized setting, these results suggest that early detection of CHF by echocardiography in patients exposed to anthracyclines may be relevant at least for patients at high risk of CHF as part of routine survivorship care. Based on our study, patients treated with >6 cycles of R-CHOP/ CHOEP may be candidates for such a screening programme. We did not find any significant differences in the risk of CHF when comparing 3 vs. 6 cycles of R-CHOP/CHOEP. This might be explained by selection bias, as 3 cycles may be preferred for patients considered at risk of cardiotoxicity or other chemo-related toxicities by the attending physician. Cumulative risk of CHF increased substantially for patients treated with >6 cycles, thus contradicting a randomized study (RICOVER-60), which found no significant difference in grade 3 or 4 cardiotoxicity between patients treated with 6 and 8 cycles (Pfreundschuh et al, 2008) . However, this might be explained by the shorter median follow-up of 2Á9 years reported by Pfreundschuh et al (2008) compared to 3Á9 years in the present study.
Pegylated and liposomal formulations of anthracyclines have been introduced as an alternative to classical anthracycline formulations to reduce cardiotoxicity (Rahman et al, 2007) . The liposomal encapsulation ensures an enhanced delivery of the drug to the tumour and a minimized delivery to organs with tight capillary junctions, such as the heart. The plasma level of free doxorubicin remains low, as the molecule is encapsulated in liposomes while in the plasma, further ensuring a lower toxicity for tumour-free organs. The polyethylene glycol coating causes a slower release of the drug to the tissue and, at the same time, protects the molecule from phagocytosis resulting in a longer half-life and reduced clearance at the tumour site (Rahman et al, 2007) . Another alternative to doxorubicin, pixantrone (R-CPOP), acts as a weak topoisomerase binder without producing cardiotoxic metabolites. While reducing the risk of cardiotoxicity (0% for R-CPOP, 6% for R-CHOP), R-CPOP was associated with poorer 3-year overall survival (69% for R-CPOP vs. 85% for R-CHOP) (Herbrecht et al, 2013) .
In conclusion, our present study confirms that anthracyclines are the main drivers of cardiotoxicity after treatment with immunochemotherapy for lymphoma. In particular, caution is needed when planning treatment with >6 cycles of R-CHOP/CHOEP, where the risk was particularly high. Patients treated without anthracyclines had a negligible risk of CHF, supporting the safety of these regimens in patients considered at substantial risk of cardiotoxicity. However, the trade-off of using alternatives to standard R-CHOP is probably poorer disease control and a judicious selection of patients for non-anthracycline therapies is important.
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